文献速递临床试验与 GCP

诊室球囊扩张术治疗气压挑战诱发咽鼓管功能障碍:随机假手术对照试验方案

In-office balloon dilation for baro-challenge-induced Eustachian tube dysfunction: study protocol for a randomized sham-controlled trial.
PubMed 文献 · Trials · 2026-06-17

该方案拟在加拿大多家三级中心开展随机假手术对照试验,纳入保守治疗失败的成人气压挑战诱发咽鼓管功能障碍患者,比较诊室局麻下球囊扩张与假手术的疗效。主要结局为术后6周BCETDQ-7症状严重度变化,次要结局包括ETDQ-7、中耳压力平衡能力、EQ-5D-5L及主观工作活动受损,随访至52周。

要点

  • 诊室球囊扩张术治疗气压挑战诱发咽鼓管功能障碍尚缺乏盲法假手术对照的高质量证据。
  • 该试验以BCETDQ-7术后6周症状变化为主要结局,并随访至52周。
  • 假手术对照设计旨在降低偏倚、提高患者报告结局的可靠性。

核心结论

  • 该试验将检验诊室球囊扩张术在减轻气压挑战诱发咽鼓管功能障碍症状方面是否优于假手术。

研究设计与样本

  • 随机、假手术对照、多中心试验,在加拿大多家三级医疗中心开展。
  • 纳入有气压挑战诱发咽鼓管功能障碍症状且保守治疗失败的成人,随机接受球囊扩张术或假手术。
  • 球囊扩张组在局麻下接受诊室球囊扩张,假手术组接受诊室假手术。

关键数值与推荐

  • 主要结局为术后6周BCETDQ-7(7项气压挑战诱发咽鼓管功能障碍问卷)症状严重度变化。
  • 次要结局包括ETDQ-7、完成中耳压力平衡动作的能力、EQ-5D-5L健康相关生活质量及主观工作与活动受损。
  • 结局在基线及术后6周、24周、52周评估。

临床怎么用

  • 若证实有效,诊室球囊扩张术可能为药物治疗失败的气压挑战诱发咽鼓管功能障碍患者提供微创治疗选择。

局限性

  • 原文指出该人群缺乏盲法假手术对照研究,限制患者报告结局的可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Balloon dilation of the Eustachian tube (BDET) is a potential treatment for Eustachian tube dysfunction (ETD). However, high-quality evidence for its efficacy in baro-challenge-induced ETD (BCETD) is lacking. Blinded, sham-controlled trials are critical in this context, particularly given the largely subjective nature of this condition. The objective of this study protocol is to test the hypothesis that BDET is superior to a sham procedure in reducing symptoms of BCETD. METHODS: This randomized, sham-controlled, multicenter trial will be conducted at multiple tertiary care centers in Canada. Adults experiencing BCETD symptoms and have failed conservative management will be randomized to undergo BDET or a sham procedure. The BDET group will undergo in-office balloon dilation under local anesthesia, while the sham group will undergo an in-office sham procedure. The primary outcome measure is the change in BCETD symptom severity as measured by the 7-item baro-challenge-induced Eustachian tube dysfunction questionnaire (BCETDQ-7), an adapted version of the 7-Item Eustachian tube dysfunction questionnaire (ETDQ-7), at 6 weeks post-procedure. Secondary outcomes include the ETDQ-7, ability to perform a middle ear pressure equalization maneuver, health-related quality of life (EQ-5D-5L questionnaire), and subjective work and activity impairment. Outcome measures will be assessed at baseline and at 6-, 24-, and 52-weeks post-procedure. DISCUSSION: BDET may offer a minimally invasive therapeutic option for BCETD patients who fail medical management, but the lack of blinded and sham-controlled studies limits the reliability of patient-reported outcomes. This trial will offer the first blinded and sham-controlled study of BDET in the BCETD population. This design aims to reduce bias and improve the reliability of patient-reported outcomes. Upon study completion and data analysis, we intend to publish our findings in a peer-reviewed journal. If BDET is found to be effective, it may offer a novel, minimally invasive treatment option for BCETD, addressing a critical gap in management of this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT05719207. Registered on 01/15/2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Aleinati M, Spiegel JL, Le TN, et al. In-office balloon dilation for baro-challenge-induced Eustachian tube dysfunction: study protocol for a randomized sham-controlled trial. Trials. 2026. PMID: 42310698. doi:10.1186/s13063-026-09853-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。